Trial Profile
Impact of Short Term Lenalidomide on Immune Response to Prevnar 13 in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Chronic lymphocytic leukaemia; Lymphocytosis
- Focus Therapeutic Use
- 15 Jan 2021 Status changed from completed to discontinued.
- 07 Oct 2019 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Planned primary completion date changed from 1 Jun 2017 to 10 Jul 2020.